๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination

โœ Scribed by Scott J. Weir; Dan C. Dimmitt; Robert C. Lanman; M. Bruce Morrill; Dennis H. Geising


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
159 KB
Volume
19
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


Diltiazem and hydrochlorothiazide are widely used to treat cardiovascular disease, often in combination. The purpose of this investigation was to determine whether a drug -drug pharmacokinetic interaction exists between diltiazem and hydrochlorothiazide. In a randomized, crossover, open study, multiple doses of diltiazem (60 mg four times daily for 21 doses) and hydrochlorothiazide (25 mg twice daily for 11 doses) were administered alone and in combination on three separate occasions to 20 healthy male volunteers. Trough and serial blood samples were collected and plasma was assayed for diltiazem, hydrochlorothiazide, and diltiazem metabolites (desacetyldiltiazem and N-desmethyldiltiazem) using HPLC. Total urine was also collected and quantified for hydrochlorothiazide.

Coadministered hydrochlorothiazide did not significantly (p \0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (C ss max ; 145 versus 158 ng mL -1 , respectively), time to maximum plasma concentration (t max ; 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUC ss ; 688 versus 771 ng โ€ข h mL -1 ), oral clearance (Cl oral ; 96.2 versus 88.0 L h -1 ), or elimination half-life (t 1/2 ; 5.2 versus 5.2 h). Similarly, administration of diltiazem did not significantly (p\0.05) influence hydrochlorothiazide (alone versus combination) C ss max (221 versus 288 ng mL -1 ), t max (1.8 versus 2.0 h), AUC ss (1194 versus 1247 ng โ€ข h mL -1 ), Cl oral (22.4 versus 21.2 L h -1 ); t 1/2 (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h -1 ). In conclusion, a clinically significant pharmacokinetic interaction between diltiazem and hydrochlorothiazide does not exist.


๐Ÿ“œ SIMILAR VOLUMES


Steady-state pharmacokinetics of the ena
โœ Jagdev Sidhu; Morten Priskorn; Mette Poulsen; Alain Segonzac; Gilles Grollier; F ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 165 KB ๐Ÿ‘ 2 views

The steady-state pharmacokinetics in serum and urine of the enantiomers of citalopram and its metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), were investigated after multiple doses of rac-citalopram for 21 consecutive days (40 mg per day) to healthy human subjects who were ext

Enantioselectivity in the steady-state p
โœ Paula Macedo Cerqueira; Evandro Josรฉ Cesarino; Fabiano Henrique Mateus; Yussif M ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

In the present study we investigated the enantioselectivity in the pharmacokinetics of metoprolol administered in a multiple-dose regimen as the racemate. The study was conducted on 10 patients of both sexes with mild to severe essential hypertension, aged 28 to 76 years, with normal hepatic and ren

STEADY STATE PHARMACOKINETICS OF CARBAMA
โœ S. Sennoune; A. Iliadis; J. Bonneton; Y. Barra; P. Genton; E. Mesdjian ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 499 KB ๐Ÿ‘ 2 views

Two carbamazepine (CBZ) tablet formulations (conventional, CBZ-CO, or controlled release, CBZ-CR) are commonly prescribed in monotherapy or in comedication with phenobarbital (PB) in the treatment of epilepsies. This study compares the pharmacokinetics of CBZ-CO against CBZ-CR in patients with epile

The Pharmacokinetics of Butorphanol and
โœ NIMISH N. VACHHARAJANI; WEN CHYI SHYU; DOUGLAS S. GREENE; RASHMI H. BARBHAIYA ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 160 KB ๐Ÿ‘ 2 views

The single-dose and steady state pharmacokinetics of butorphanol and its metabolites, hydroxybutorphanol (HO-B) and norbutorphanol (NOR-B), were studied in nine healthy male volunteers. Each subject received a single 1 mg dose of butorphanol on days 1 and 6, and a 1 mg dose every 6 h (q6h) on days 2

THE RELATIVE BIOAVAILABILITY OF TWO MARK
โœ C. L. Lippert; T. Arumugham; V. O. Bhargava; M. Eller; S. J. Weir ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 472 KB ๐Ÿ‘ 2 views

This study was conducted to determine the relative bioavailability of Dilacorm XR capsules compared to CardizemD CD capsules at both low (180mgdPL) and high (540mgd-') dose levels. Trough and serial plasma samples were obtained and pharmacokinetic parameters were calculated from the steady state con

Lack of effect of food on the steady sta
โœ Nuggehally R. Srinivas; Wen C. Shyu; James Lee; Douglas S. Greene; Rashmi H. Bar ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 128 KB ๐Ÿ‘ 1 views

The effect of food on the pharmacokinetics of BMS-181101, a new anti-depressant under development, was investigated in 12 healthy male volunteers at steady state. Each subject received a 15 mg oral dose of BMS-181101 twice a day (q 12 h) for 11 days and a morning dose of BMS-181101 on day 12. Six su